Bioactivity Of Opioidmimetic Substances
阿片类物质的生物活性
基本信息
- 批准号:8149072
- 负责人:
- 金额:$ 29.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
A series of novel Dmt-Tic pharmacophoric drugs or protodrugs exhibited antagonism in vitro and in vivo using the hot-plate (supraspinal effects, the central nervous system) and tail-flick test (spinal effects). The control compounds exhibited central (CNS) mediated analgesia and were orally bioavailable opioidmimetics. Interestingly, N,N-dimethyl-Dmt-Tic-NH-adamantane and H-Dmt-Tic-NH--tert-butyl derivatives inhibited tolerance to morphine in mice, which suggests that the multidrug resistance P-glycoprotein 1 was involved due to their inhibition in vitro of Pg-1. Other Dmt-Tic compounds, such as MZ-2, in particular (patent application pending) prevents the formation of tolerance to morphine. Furthermore, the elimination of tolerance occurred without the severe side-effects seen with both naloxone and naltrexone, a FDA approved drug for the treatment of alcoholism. MZ-2 effectively and completely eliminated withdrawal symptoms and tolerance following either acute or chronic morphine addiction in mice. In addition, MZ-2 decreased food intake in ob/ob mice and diet-induced obesity mice models, altered the levels of several key indicators of obesity in the clinical analyses of blood samples. Importantly, MZ-2 elevated bone mineral density in vivo and increased the osteocalcin formation in cell cultures in vitro about 30%, whereas naltrexone was only about 17% effective; morphine decreased this phenomenon by 17%. These data suggestion the potential application of MZ-2 in fighting bother obesity and osteoporosis in human populations.
一系列新型Dmt-Tic药理学药物或原型药物在体外和体内使用热板(脊髓上作用,中枢神经系统)和甩尾试验(脊髓作用)表现出拮抗作用。对照化合物表现出中枢(CNS)介导的镇痛作用,是口服生物可利用的阿片样物质。 有趣的是,N,N-二甲基-Dmt-Tic-NH-金刚烷和H-Dmt-Tic-NH-叔丁基衍生物抑制小鼠对吗啡的耐受性,这表明由于它们在体外抑制Pg-1,因此涉及多药耐药P-糖蛋白1。 其他Dmt-Tic化合物,如MZ-2,特别是(专利申请待审)防止对吗啡耐受性的形成。 此外,耐受性的消除发生在没有纳洛酮和纳洛酮(FDA批准的用于治疗酒精中毒的药物)的严重副作用的情况下。MZ-2能有效地消除小鼠急性或慢性吗啡成瘾后的戒断症状和耐受性。 此外,MZ-2减少了ob/ob小鼠和饮食诱导的肥胖小鼠模型的食物摄入量,改变了血液样本临床分析中肥胖的几个关键指标的水平。 重要的是,MZ-2在体内提高了骨密度,在体外细胞培养中增加了约30%的骨钙素形成,而纳洛酮仅有效约17%;吗啡降低了17%。 这些数据表明MZ-2在对抗人类肥胖和骨质疏松症中的潜在应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAWRENCE H LAZARUS其他文献
LAWRENCE H LAZARUS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}